Analysts See $-0.32 EPS for aTyr Pharma, Inc. (LIFE)

July 14, 2018 - By Richard Slagle

aTyr Pharma, Inc. (NASDAQ:LIFE) Logo

Analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to report $-0.32 EPS on August, 13.They anticipate $0.19 EPS change or 37.25 % from last quarter’s $-0.51 EPS. After having $-0.36 EPS previously, aTyr Pharma, Inc.’s analysts see -11.11 % EPS growth. The stock decreased 2.74% or $0.03 during the last trading session, reaching $0.94. About 1.91 million shares traded or 158.91% up from the average. aTyr Pharma, Inc. (NASDAQ:LIFE) has declined 72.94% since July 14, 2017 and is downtrending. It has underperformed by 85.51% the S&P500.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Among 3 analysts covering aTyr Pharma (NASDAQ:LIFE), 0 have Buy rating, 3 Sell and 0 Hold. Therefore 0 are positive. aTyr Pharma had 3 analyst reports since February 14, 2018 according to SRatingsIntel. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Sell” rating by Citigroup on Tuesday, May 15. J.P. Morgan downgraded the stock to “Sell” rating in Wednesday, February 14 report. The stock has “Underweight” rating by JP Morgan on Wednesday, February 14.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $28.04 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.